Leadership Team
Aimabs is led by seasoned executives across regulatory affairs, clinical development, commercialization, and legal/compliance, bringing deep U.S./Western experience and on-the-ground China execution.
Advisory Board
Yan Zhao
MD, EMBA
• Former senior executive at Novartis/Roche/BMS
• Led clinical development and registration of blockbuster therapies in China
Liang Zhao
PhD
• Former FDA Division Director (Quantitative Methods)
• UCSF Professor
• Expert in bridging global standards with China data requirements
Shuo Chen
PhD
• University of Maryland Professor
• AI and biomedical data modeling expert
• Extensive clinical trial statistics experience
Yaning Wang
PhD
• Former FDA Pharmacometrics Division Director
• Advises on dose optimization and global development strategy
Guang Gao
PhD
• Former FDA China GMP expert
• PATH senior technical officer
• Supports global quality and CMC strategy
Aimabs is supported by an advisory board of global leaders across regulatory science, quantitative methods, clinical development, AI/biostatistics, pharmacometrics, and CMC/GMP strategy—strengthening execution excellence for both inbound and outbound programs.
Links
-
ꁸ Top
-
ꂅ 88888888
-
ꀥ QR code
